Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 149

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 149
---
 physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain
other health care providers beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by physicians
and their immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in
the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist
assistants and certified nurse midwives. Certain foreign countries and U.S. states also mandate implementation of commercial compliance
programs, impose restrictions on device manufacturer marketing practices and require tracking and reporting of gifts, compensation and
other remuneration to health care professionals and entities.

Penalties for violation of
any of the health care laws described above or any other governmental regulations that apply to us include, without limitation, civil,
criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs,
such as Medicare and Medicaid, injunctions, refusal to allow us to enter into government contracts, contractual damages, reputational
harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of an entity’s operations

Employees

As of the date of this prospectus,
we have three members of our senior management that are engaged as external service providers and four part-time employees. In addition,
we have three part-time personnel engaged in research and development. We are not bound by any collective bargaining agreements. We consider
the relationship with our employees to be good. We also use outside consultants and contractors with special expertise and skills for
limited engagements, including manufacturing and quality assurance. We plan to contract with a contract research organization that
is knowledgeable and experienced in developing, testing and commercializing medical solutions.

<div align='center'>87</div>

Facilities

We do not have manufacturing
facilities. We operate out of our offices in Herzliya 4676652, Israel that are being provided for a monthly fee of $5,500 (including $3,000
for administrative expenses). We expect to lease additional space as we expand the team upon conclusion of this offering.

Legal Proceedings

CSL Behring GmbH Payment Dispute

In 2019, a controversy
has arisen between us and CSL Behring GmbH, or CSL, whether certain unshipped minimum purchase commitments for fibrinogen from 2018 to
2020 are to be paid by us pursuant to